Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib vs Sorafenib in Refractory Advanced RCC
NCT02627963Phase 3Completed
- Sponsor
- AVEO Oncology
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of tivozanib in renal cell carcinoma (RCC) (2 arms), sponsored by AVEO Oncology. Primary endpoint: Progression-Free Survival up to 5 years. Started May 2016; status: completed.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02627963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627963.